LifeMD, Inc. (NASDAQ:LFMD) Receives Average Rating of "Buy" from Analysts

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $12.86.

A number of equities research analysts have weighed in on the stock. Lake Street Capital set a $18.00 price target on shares of LifeMD and gave the company a "buy" rating in a report on Thursday. HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of LifeMD in a report on Wednesday, April 30th. Finally, BTIG Research upped their price target on shares of LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, June 18th.

LifeMD Trading Down 3.7%

LFMD stock traded down $0.44 during trading on Thursday, hitting $11.52. The company had a trading volume of 390,386 shares, compared to its average volume of 1,082,066. The firm has a market capitalization of $523.58 million, a price-to-earnings ratio of -34.00 and a beta of 2.40. The business has a 50 day moving average of $11.71 and a 200 day moving average of $7.72. LifeMD has a fifty-two week low of $3.99 and a fifty-two week high of $15.84.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.05. The company had revenue of $65.70 million during the quarter, compared to analyst estimates of $62.47 million. As a group, equities analysts predict that LifeMD will post -0.56 EPS for the current year.

Insider Buying and Selling

In other LifeMD news, insider Eric Harold Yecies sold 15,000 shares of the business's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $12.25, for a total transaction of $183,750.00. Following the sale, the insider owned 16,100 shares in the company, valued at approximately $197,225. The trade was a 48.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Stefan Galluppi sold 85,000 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $12.38, for a total value of $1,052,300.00. Following the completion of the transaction, the insider owned 80,449 shares in the company, valued at $995,958.62. This represents a 51.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 346,995 shares of company stock worth $4,119,172 in the last quarter. 18.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LifeMD

A number of large investors have recently made changes to their positions in the business. CWM LLC increased its holdings in shares of LifeMD by 17.5% in the 1st quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after purchasing an additional 1,351 shares during the period. Prudential Financial Inc. increased its holdings in shares of LifeMD by 19.3% in the 4th quarter. Prudential Financial Inc. now owns 13,605 shares of the company's stock valued at $67,000 after purchasing an additional 2,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of LifeMD by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company's stock valued at $270,000 after buying an additional 2,235 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of LifeMD by 26.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock valued at $70,000 after buying an additional 2,895 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of LifeMD by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 822,217 shares of the company's stock valued at $4,071,000 after buying an additional 2,984 shares in the last quarter. Institutional investors and hedge funds own 35.52% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.